P17.89 EFFECTS OF GLIOBLASTOMA FIRST-LINE TRIALS ON TIME DELAY TO INITIATION OF TREATMENT, SIGNS OF EARLY TUMOR PROGRESSION AND PROGRESSION-FREE SURVIVAL

Por Sefranek, D., Wendl, C., Hutterer, M., Hau, P., Uhl, M.
Publicado em 2014

The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-β2

Por Arslan, F, Bosserhoff, A-K, Nickl-Jockschat, T, Doerfelt, A, Bogdahn, U, Hau, P
Publicado em 2007

P01.11 ATF4 AS A MEDIATOR OF RESISTANCE TO TARGETED THERAPY IN HIGH-GRADE GLIOMAS

Por Moeckel, S., Neyns, B., Pan, E., Riemenschneider, M., Bosserhoff, A., Vollmann-Zwerenz, A., Hau, P.
Publicado em 2014

Intraventricular cytarabine in a case of idiopathic hypertrophic pachymeningitis

Por Kleiter, I, Hans, V, Schuierer, G, Marienhagen, J, Hau, P, Schutz, H, Bogdahn, U, Steinbrecher, A
Publicado em 2004

OS7.7 Feasibility and toxicity of concomitant radiochemotherapy with vincristine in adult patients with medulloblastoma - results from the NOA-07 trial

Por Seidel, C., Reimers, C., Beier, D., Pietsch, T., Warmuth-Metz, M., Bogdahn, U., Kortmann, R., Hau, P.
Publicado no Neuro Oncol (2016)

P17.39 TURN OLD INTO NEW: METFORMIN AS ANTINEOPLASTIC AGENT IN GLIOBLASTOMA

Por Seliger, C., Renner, K., Kreutz, M., Meyer, A., Jachnik, B., Bogdahn, U., Vollmann-Zwerenz, A., Hau, P.
Publicado em 2014

OS02.1 Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma - the NOA-07 trial

Por Beier, D., Proescholdt, M., Reinert, C., Hattingen, E., Seidel, C., Dirven, L., Lürding, R., Pfister, S., Pietsch, T., Hau, P.
Publicado no Neuro Oncol (2017)

P01.37 Impact of C/EBPβ isoforms on brain tumor initiating cells

Por Vollmann-Zwerenz, A., Sponton, S., Jachnik, B., Weigell, P., Lorenz, J., Schulze, M., Bogdahn, U., Riemenschneider, M. J., Hau, P.
Publicado no Neuro Oncol (2017)

P09.20 Effect of age on outcome in the GLARIUS trial

Por Kebir, S., Schaefer, N., Hattingen, E., Steinbach, J., Weyerbrock, A., Hau, P., Goldbrunner, R., Proescholdt, M., Herrlinger, U., Glas, M.
Publicado no Neuro Oncol (2017)

Low Entomological Impact of New Water Supply Infrastructure in Southern Vietnam, with Reference to Dengue Vectors

Por Tran, Hau P., Huynh, Trang T. T., Nguyen, Yen T., Kutcher, Simon, O'Rourke, Peter, Marquart, Louise, Ryan, Peter A., Kay, Brian H.
Publicado em 2012

P16.11 Complete resection is not associated with improved survival in MGMT non-methylated glioblastoma. Results from the GLARIUS trial

Por Kebir, S., Stummer, W., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Proescholdt, M., Vatter, H., Herrlinger, U., Glas, M.
Publicado no Neuro Oncol (2017)

P03.02 IN SITU ORGANOTYPIC SLICE CULTURE MIGRATION MODEL TO DISSECT INFILTRATIVE FROM STATIONARY HUMAN BRAIN TUMOR INITIATING CELLS

Por Gawrisch, V., Patwary, N., Rüttgers, M., Kerkhoff, E., Riemenschneider, M.J., Bogdahn, U., Vollmann-Zwerenz, A., Klein, C.A., Hau, P.
Publicado em 2014

O10.04 THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL...

Por Herrlinger, U., Schäfer, N., Steinbach, J.P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.
Publicado em 2014

OS06.3 Characterisation of human brain tumour initiating cells leading invasion

Por Leidgens, V. J., Alieva, M., Lu, X., Patwary, N., Kerkhoff, E., Proescholdt, M. J. M., Vollmann-Zwerenz, A., van Rheenen, J., Klein, C. A., Hau, P.
Publicado no Neuro Oncol (2017)

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Por Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N.K., Mahapatra, A.K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K.-H.
Publicado em 2011

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Por Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Publicado em 2009

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Por Stupp, R., Tosoni, A., Bromberg, J. E. C., Hau, P., Campone, M., Gijtenbeek, J., Frenay, M., Breimer, L., Wiesinger, H., Allgeier, A., van den Bent, M. J., Bogdahn, U., van der Graaf, W., Yun, H. J., Gorlia, T., Lacombe, D., Brandes, A. A.
Publicado em 2011

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Por Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, S W, Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J, Illerhaus, G
Publicado no Leukemia (2017)